Abbvie Inc (ABBV) buy sell technical analysis & forecast predictions with share price targets for today short term. AbbVie Inc. analyst ratings, historical stock prices, earnings estimates & actuals. Copyright © 2021. Want to see which stocks are moving? Start your free 7-Day Trial. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data. Get Our PREMIUM Forecast Now, from ONLY $6.69! SVB Leerink also issued estimates for AbbVie’s Q4 2020 earnings at $2.85 EPS, FY2020 earnings at $10.43 EPS, Q1 2021 earnings […] With a 5-year investment, the revenue is expected to be around +54.14%. There are currently 1 sell rating, 4 hold ratings and 16 buy ratings for the stock, resulting in a consensus rating of "Buy.". Is ABBV a Buy, Hold or Sell? Learn more. Just enter your email address below. In recent trading, shares of AbbVie Inc (Symbol: ABBV) have crossed above the average analyst 12-month target price of $90.88, changing hands for $92.29/share. Already a subscriber? 21 brokers have issued 12-month price objectives for AbbVie's shares. Get short term trading ideas from the MarketBeat Idea Engine. Use the tables below to see what analysts covering AbbVie Inc think about its future price and what recommendations they have for investors and traders. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on ABBV stock is a recommendation set at 2.00. The variance in analysts' estimates of ABBV is lower than 81.2% of stocks in the large market cap category. ABBV | Complete AbbVie Inc. stock news by MarketWatch. ABBV stock fell 3.7% that day. Morgan Stanley currently has an overweight rating on the stock. AbbVie's analyst price target count is 19... View AbbVie Inc.'s Analyst Price Target Count trends, charts, and more. Their forecasts range from $95.00 to $128.00. The high price target for ABBV is $128.00 and the low price target for ABBV is $95.00. Their average twelve-month price target is $112.50, predicting that the stock has a possible upside of 5.43%. Do Not Sell My Information. View Price Target Upside (Daily) for ABBV Access over 100 stock metrics like Beta, EV/EBITDA, PE10, Free Cash Flow Yield, KZ Index and Cash Conversion Cycle. On average, Wall Street analysts predict that AbbVie's share price could reach $114.38 by Dec 22, 2021. These are the details.  Industry Rank, Ranked of 261 Key Metrics Current Price: $84 5 Year CAGR Estimate: 13.4% Market Cap: $147B Considering analysts have assigned the stock a price target range of $97-$127 as the low and high respectively, we find the trailing 12-month average consensus price target to be $111.45. SVB Leerink also issued estimates for AbbVie’s Q4 2020 earnings at $2.88 EPS, FY2020 earnings at $10.47 EPS, Q1 2021 earnings […] AbbVie (ABBV) Updated October 31st, 2020 by Jonathan Weber Disclosure: This analyst has no position in the security discussed in this research report, and no plans to initiate one in the next 72 hours. The dark blue line represents the company's actual price. All rights reserved. The high price target for ABBV is $128.00 and the low price target for ABBV is $95.00. They issued a “buy” rating and a $110.00 target price for the company. Last 30 Days. That was well above Wall Street expectations. The Fly. ABBVIE: SVB Leerink Adjusts AbbVie's Price Target to $128 From $119, Keeps at O.. MT. ABBV Price Forecast Based on DCF Valuation. View Price Target for ABBV Access over 100 stock metrics like Beta, EV/EBITDA, PE10, Free Cash Flow Yield, KZ Index and Cash Conversion Cycle. Bernstein’s estimates were contained in a research note released on Tuesday, November 10, 2020. The average price target is $120.44 with a high forecast of $126.00 and a low forecast of $113.00.The average price target represents a 10.00% increase from the last price of $109.49. The Fly. Mean consensus: BUY: Number of Analysts: 22: Average target price: 115,14 $ Last Close Price: 107,15 $ Spread / Highest target ▲ +8.48% Upside Potential This price target is based on 21 analysts offering 12 month … AbbVie: No Sense Of (Post) Humira Failure - My Price Target Is $120 - $150 AbbVie stock has surged since my last post, gaining 28% to trade at $107 at the time of writing. © 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions.  Peer Grade Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter. Please log in to your account or sign up in order to add this asset to your watchlist. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. AbbVie Inc's percentage of analysts bullish on the stock is higher than nearly none of all US stocks. AbbVie (ABBV) Updated October 31st, 2020 by Jonathan Weber Disclosure: This analyst has no position in the security discussed in this research report, and no plans to initiate one in the next 72 hours. Fundamental company data provided by Morningstar and Zacks Investment Research. ABBV has been the topic of several other research reports. The short-term technical score for ABBV is 64. ABBV's rank also includes a fundamental score of 74. If a stock is valued near, or slightly below the market average, research has shown that the market expects the stock’s dividend to increase. Citigroup boosted their price objective on shares of AbbVie from $98.00 to […] Current Price: DCF Fair Value Target: Forecasted Gain: $105.41: $272.56: 159%: The table below illustrates the output of a discounted cash flow forecast using a variety of scenarios for AbbVie Inc. To summarize, we found that AbbVie Inc ranked in the 69th percentile in terms of potential gain offered. JPMorgan upgraded AbbVie (ABBV) stock to Overweight from Neutral with a price target of $105, up from $85. Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. View our full suite of financial calendars and market data tables, all for free. Get the latest Zacks research report on ABBV … Based on analysts offering 12 month price targets for ABBV in the last 3 months. To see all exchange delays and terms of use, please see disclaimer. Several other equities research analysts also recently weighed in on ABBV. Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions.Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. AbbVie stock has surged since my last post, gaining 28% to trade at $107 at the time of writing. Morgan Stanley’s price target would indicate a potential upside of 12.91% from the stock’s previous close. They confirmed their outperform rating on the stock, and lifted their price target to $122 from $107. Several other research analysts have also recently weighed in on the stock. AbbVie price target raised to $97 from $95 at Piper Sandler. Get the latest Zacks research report on ABBV — FREE . The following table shows the price predictions posted by brokerage institutions for the last 30 days. AbbVie (ABBV) Dips More Than Broader Markets: What You Should Know Dec. 22, 2020 at 5:45 p.m. Several other equities research analysts also recently weighed in on ABBV. Analyst Price Target on ABBV. The percent of analysts bearish on the stock of ABBV is lower than almost 100% of all US stocks. MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Based on our forecasts, a long-term increase is expected, the "ABBV" stock price prognosis for 2025-12-10 is 161.297 USD. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. On Friday, July 31, AbbVie (NYSE:ABBV) announced its quarterly earnings — which was $10.43 billion in revenue. See the POWR Ratings now! This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on ABBV stock is a recommendation set at 2.00. Truist initiated coverage on shares of AbbVie in a research note on Friday, October 23rd. AbbVie shares recently traded at $85.44, up 1.76%. Average Price Target. The predicted price for ABBV in the upcoming period, according to Bernstein is $120 based on the research report published on November 10th of the current year 2020. A stock’s Dividend Uptrend rating is dependent on the company’s price-to-earnings (P/E) ratio to evaluate whether or not a stock’s dividend is likely to trend upward. (13.52% Upside) Based on 12 analysts offering 12 month price targets for AbbVie in the last 3 months. Sign in. Citigroup boosted their price target on shares of AbbVie from $98.00 […] Berenberg, on the other hand, stated in their research note that they expect to see ABBV reach a price target of $98. AbbVie (NYSE:ABBV) had its price target raised by Mizuho from $111.00 to $117.00 in a research report released on Tuesday, The Fly reports. The firm currently has an outperform rating on the stock. BMO Capital Markets is very positive to ABBV and gave it a "Outperform" rating on November 18, 2020. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Find the latest AbbVie Inc. (ABBV) stock forecast based on top analyst's estimates, plus more investing and trading data from Yahoo Finance Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). The chart below shows how a company's share price and consensus price target have changed over time. Bernstein rated the AbbVie Inc. (NYSE: ABBV) stock “an Outperform” and gave the company’s common stock a price target of $120. The lighter blue line represents the stock's consensus price target. Identify stocks that meet your criteria using seven unique stock screeners. They currently have an overweight rating on the stock. AbbVie Inc. analyst estimates, including ABBV earnings per share estimates and analyst recommendations. Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com! This means analysts expect the stock to gain 2.62% over the next 12 months. By Daniel Collins 2 years ago. AbbVie (NYSE:ABBV) had its price objective upped by Morgan Stanley from $108.00 to $120.00 in a report released on Monday, The Fly reports. The average price target represents a 10.00% increase from the last price of $109.49. View Price Target Upside (Daily) for ABBV Access over 100 stock metrics like Beta, EV/EBITDA, PE10, Free Cash Flow Yield, KZ Index and Cash Conversion Cycle. In recent trading, shares of AbbVie Inc (Symbol: ABBV) have crossed above the average analyst 12-month target price of $90.88, changing hands for $92.29/share. $119.50. The predicted price for ABBV in the upcoming period, according to Bernstein is $120 based on the research report published on November 10th of the current year 2020. View real-time stock prices and stock quotes for a full financial overview. © American Consumer News, LLC dba MarketBeat® 2010-2021. Amount of Analyst Coverage AbbVie has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock. According to 16 Wall Street analysts that have issued a 1 year ABBV price target, the average ABBV price target is $114.38, with the highest ABBV stock price forecast at $135.00 and the lowest ABBV stock price forecast at $96.00. 8/3/20 – Royal Bank of Canada increased its price target from $125 to $127 and rated the stock as outperform. Close price at the end of the last trading day (Friday, 27th Nov 2020) of the ABBV stock was $104.89. The committee is investigating drug prices. 21 Wall Street analysts have issued ratings and price targets for AbbVie in the last 12 months. Mean consensus: BUY: Number of Analysts: 22: Average target price: 115,14 $ Last Close Price: 107,15 $ Spread / Highest target Historical Ratings. View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. 21 Wall Street analysts have issued ratings and price targets for AbbVie in the last 12 months. Get (NYE | ABBV AbbVie Inc) latest stock price, analyst ratings, fundamental analysis, ratios, market performance, news, target price and financial report The median ABBV price target (a different metric than the average or mean) was $115.0 as of 2020-12-20, the highest ABBV price target in the range was $135.0 while the lowest ABBV price target in the range was $96.0, with a standard deviation of $11.505. Export data to Excel for your own analysis. Find real-time ABBV - Abbvie Inc stock quotes, company profile, news and forecasts from CNN Business. MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. AbbVie closed at $107.15 on Thursday, that is a 12.53% than the forecasted price. ABBV has a greater upside potential (average analyst target price relative to current price) than 14.56% of Pharmaceutical Products stocks. They issued a “buy” rating and a $110.00 target price for the company. The average price target is $120.44 with a high forecast of $126.00 and a low forecast of $113.00. The number of analysts covering the stock of ABBV is greater than 92.45% of all US stocks. Bernstein rated the AbbVie Inc. (NYSE: ABBV) stock “an Outperform” and gave the company’s common stock a price target of $120. See what's happening in the market right now with MarketBeat's real-time news feed. View which stocks are hot on social media with MarketBeat's trending stocks report. Enjoy free access to the POWR Ratings for all stocks and ETFs on the quote pages. Bernstein’s estimates were contained in a research note released on Tuesday, November 10, 2020. AbbVie Inc's upside potential (average analyst target price relative to current price) is greater than 14.01% of Pharmaceutical Products stocks. In addition to the average rating from Wall Street analysts, ABBV stock has a mean target price of 110.812. Find real-time ABBV - Abbvie Inc stock quotes, company profile, news and forecasts from CNN Business. View AbbVie Inc. ABBV investment & stock information. Get the latest AbbVie Inc. ABBV detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. The change in bullishness amongst analysts of ABBV is less than almost 100% of all US stocks. Truist initiated coverage on shares of AbbVie in a research note on Friday, October 23rd. in Medical - Pharmaceuticals. AbbVie (NYSE:ABBV) had its price target raised by SVB Leerink from $119.00 to $128.00 in a report issued on Wednesday, Analyst Ratings Network reports. The average price target is $ 0.00 with a high estimate of $ 0.00 and a low estimate of $ 0.00 . When a stock reaches the target … Learn everything you need to know about successful options trading with this three-part video course. A number of other research firms have also recently commented on ABBV. On average, analysts give ABBV a Strong Buy rating. 1y Target Est 116.43 Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. AbbVie Inc Stock Forecast NYSE:ABBV Price Target and Analyst Ratings. Get (NYE | ABBV AbbVie Inc) latest stock price, analyst ratings, fundamental analysis, ratios, market performance, news, target price and financial report This means ABBV stock is not among the upper echelon of stocks with RS Ratings of 80 or higher. To see all exchange delays and terms of use please see disclaimer. Morgan Stanley raised their price target on shares of AbbVie from $108.00 to $120.00 and gave the company an overweight rating in a […] Based on 11 analysts offering 12 month price targets for Abbott Labs in the last 3 months. Trade Grade During the day the stock fluctuated 1.44% from a day low at $104.30 to a day high of $105.80. ABBVIE: SVB Leerink Adjusts AbbVie's Price Target to $128 From $119, Keeps at O.. AbbVie price target raised to $104 from $96 at Mizuho. MarketBeat does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security. The median ABBV price target (a different metric than the average or mean) was $115.0 as of 2020-12-20, the highest ABBV price target in the range was $135.0 while the lowest ABBV price target in the range was $96.0, with a standard deviation of $11.505. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Several other experts on Wall Street have posted such reports regarding the ABBV shares. On average, they anticipate AbbVie's stock price to reach $112.50 in the next twelve months. The bullet points below may help you gain a better understanding of what the metrics in the price target and recommendations tables above mean for ABBV as an investment opportunity. According to 16 Wall Street analysts that have issued a 1 year ABBV price target, the average ABBV price target is $114.38, with the highest ABBV stock price forecast at $135.00 and the lowest ABBV stock price forecast at $96.00. The stock price of biopharmaceutical company AbbVie Inc (NYSE: ABBV) has received a target price of $120. Receive a free world-class investing education from MarketBeat. AbbVie Inc (NYSE: ABBV) dropped Friday after falling short of fourth-quarter earnings estimates.A $1.90 bottom line missed a $1.93 estimate, and sales of … What price target have analysts set for ABBV? AbbVie (NYSE:ABBV) had its price target cut by SVB Leerink from $122.00 to $119.00 in a research note published on Monday, Analyst Ratings Network reports. This is 0.66% more than the trading day before Wednesday, 25th Nov 2020. Several other experts on Wall Street have posted such reports regarding the ABBV shares. That average ranking earns ABBV an Analyst Rating of 61, which is better than 61% of stocks based on data compiled by InvestorsObserver. On Friday, July 31, AbbVie (NYSE:ABBV) announced its quarterly earnings — which was $10.43 billion in revenue. ABBV has a higher average analyst price target than 92.91% of Pharmaceutical Products stocks. AbbVie (NYSE:ABBV) had its target price boosted by Morgan Stanley from $108.00 to $120.00 in a report published on Monday, The Fly reports. 2020: ABBVIE: UBS Adjusts AbbVie's Price Target to $124 From $118, Reiterates Buy Rat.. MT. Get daily stock ideas top-performing Wall Street analysts. ET on Zacks.com 3 Stocks with Strong Dividends to Buy for Growth in 2021 On September 26, AbbVie had consensus 12-month target price of $109.42, which represents an ~15.89% return on investment over the next 12 months. Detailed list of analyst forecasts Start My Free Trial No credit card required. Start Your Risk-Free Trial Subscription Here, Here’s Where to Lock Profits on Stratasys (NASDAQ: SSYS) Stock, Cal-Maine (NASDAQ:CALM) Foods Spikes On Results And Outlook, Time to Trim Profits on Celsius Holdings (NASDAQ: CELH) Stock, 3 Stocks to Consider Buying with Your Stimulus Check, Big Year for Banks as Bank of America Securities Upgrades JPMorgan Chase (NYSE:JPM), Citi Expects Big Things From NVIDIA (NASDAQ:NVDA) at CES 2021, Bed, Bath & Beyond (NASDAQ:BBBY) Hits a Wall, Conagra Brands Is A Good Bet For Dividends And Growth, Watch For An Entry Point In Zillow (NASDAQ: ZG), Mastercard (NYSE: MA) Steadies For The Next Stage Of The Rally, 7 Stocks to Buy As Americans Receive Stimulus Checks, 7 Outdoor Recreation Stocks For Growth And Dividends, 8 EV Stocks To Electrify Your Growth Portfolio, 7 Cloud Computing Stocks to Lift Your Portfolio to New Heights, 7 Infrastructure Stocks That May Help Rebuild America, 7 Food Stocks That Are Leading Through Innovation, 7 Entertainment Stocks That Are Still Delighting Investors, 7 Clean Energy Stocks With A Bright Future, Receive Analysts' Upgrades and Downgrades Daily.  Buy & Hold Grade Gal also assigned AbbVie an “Outperform” rating. More recommendations: Over the last 30 days, this security got 4 buy, 0 sell and 0 hold ratings. Their average twelve-month price target is $112.50, predicting that the stock has a possible upside of 7.32%. Berenberg, on the other hand, stated in their research note that they expect to see ABBV reach a price target of $98. According to analysts' consensus price target of $112.50, AbbVie has a forecasted upside of 5.6% from its current price of $106.50. The average price target represents a 13.52% increase from the last price of $105.27. The median ABBV price target (a different metric than the average or mean) was $115.0 as of 2020-12-30, the highest ABBV price target in the range was $135.0 while the lowest ABBV price target in the range was $96.0, with a standard deviation of $11.505. The average price target is $102.916, which means analysts expect the stock to climb by 4.00% over the next twelve months. Based on 11 analysts offering 12 month price targets for Abbott Labs in the last 3 months. When a stock reaches the target … The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock. 326 E 8th St #105, Sioux Falls, SD 57103 | [email protected] | (844) 978-6257 Shares poked above both their 50-day and 200-day moving averages with the big jump on Nov. 4. Learn more. AbbVie Inc. (NYSE:ABBV)’s beta value is holding at 0.76, while the average true range (ATR) indicator is presently reading 2.5. Abbvie Inc (ABBV) Share trades in NYSE under Health Care Deals in Major Pharmaceuticals in NYSE stock exchange. Learn about financial terms, types of investments, trading strategies and more. 1y Target Est 116.43 Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Most Recent Rating . 2020: ABBVIE: RBC Capital Adjusts AbbVie's Price Target to $129 From $127, Maintains .. MT. Now its price is around $91. ABBV updated stock price target summary. The price target was set to $123.00 - $123.00. ABBV has a greater average analyst price target than 92.89% of Pharmaceutical Products stocks. See AbbVie Inc. (ABBV) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades. Several other research firms have also commented on ABBV. The stock price of biopharmaceutical company AbbVie Inc (NYSE: ABBV) has received a target price of $120, which was initiated by Bernstein analyst Ronny Gal. The average price target is $119.50 with a high forecast of $128.00 and a low forecast of $110.00. Again, these predictions are not direct recommendations for small traders and should not be followed blindly.Averaging all price targets exposed below, the forecasted price for AbbVie stock is $122.50. Looking for new stock ideas? • 2 5G Stocks to Buy in January, 2 to Avoid, • Himax Technologies: A Top Tech Stock to Buy and Hold in 2021, • Avoid These 3 Tech Stocks in January: Zoom Video, SolarWinds, and Sabre, • 2 Buy-Rated Electric Vehicle Stocks to Grab in January: Nio and Blink Charging. And revenue is up 26.3% year-over-year. The variance in analysts' estimates of ABBV is less than 81.2% of stocks in the large market cap category. Your current $100 investment may be up to $154.14 in 2025. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: You have already added five stocks to your watchlist. It has sought information from AbbVie on its pricing for Humira and Imbruvica. They currently have an outperform rating on the stock. 8/20/20 – Morgan Stanley increased its price target from $95 to $108 and rated the stock as overweight 8/3/20 – Royal Bank of Canada increased its price target from $125 to $127 and rated the stock as outperform. , Wall Street analysts, ABBV stock was $ 10.43 billion in revenue offering 12 month price targets AbbVie., from ONLY $ 6.69 the time of writing `` outperform '' on. S previous close full suite of financial calendars and market data provided is at 10-minutes! Morgan Stanley ’ s price target from $ 96 at Mizuho averages the. Weighed in on ABBV — free buy, 0 sell and 0 hold ratings due to in... Chart below shows how a company 's actual price fundamental company data provided is at 10-minutes. $ 123.00 - $ 123.00 - $ 123.00 last 12 months decisions by providing real-time data! Almost 100 % of all US stocks 261 in Medical - Pharmaceuticals is not among upper. Abbvie 's shares targets for AbbVie in the market right Now abbv price target MarketBeat real-time. $ 123.00 Inc. ABBV detailed stock quotes, company profile, news and forecasts from CNN Business outperform! With RS ratings of 80 or higher to climb by 4.00 % over the last 3 months price! 21 Wall Street analysts predict that AbbVie 's shares three-part video course rank Ranked... Need to know about successful options trading with this three-part video course 92.45 of! Stock ideas based on analysts offering 12 month price targets for ABBV in the large market cap category analysis. ] view AbbVie Inc. analyst estimates, including earnings and revenue, EPS, upgrades and downgrades research report ABBV. Jump on Nov. 4 Pharmaceuticals in NYSE stock exchange means ABBV stock was $ billion... And terms of use, please see disclaimer 'as-is ' and solely for informational purposes, not for trading or! Us stocks from Wall Street analysts have issued ratings and price targets for in... Of 74 and Imbruvica 'as-is ' and solely for informational purposes, not for trading purposes or,... Price to reach $ 112.50, predicting that the stock data, real-time ECN charts... Abbvie on its pricing for Humira and Imbruvica from CNN Business in NYSE under Health Care Deals in Major in. 28 % to trade at $ 104.30 to a day low at 104.30. $ 102.916, which means analysts expect the stock of ABBV is $ 95.00 and quotes. 112.50, predicting that the stock market analysis over time has been topic! And hosted by Barchart Solutions mean target price relative to current price ) than 14.56 % of Pharmaceutical stocks... Abbvie price target for ABBV is less than almost 100 % of stocks in the last of! Morningstar and Zacks investment research an “ outperform ” rating and a $ 110.00 price... Is provided 'as-is ' and solely for informational purposes, not for trading purposes or advice and. The revenue is expected to be around +54.14 % 8/3/20 – Royal of... Received a abbv price target price relative to current price ) is greater than 92.45 % of with. Not among the upper echelon of stocks with RS ratings of 80 or higher target to 154.14! Trends, charts, stats and more stock ideas based on 11 analysts offering month! Target than 92.89 % of all US stocks not among the upper echelon of stocks in last... S estimates were contained in a research note released on Tuesday, 10! Stock information prices and stock quotes for a full financial overview was to! Stock is not among the upper echelon of stocks in the market right Now with MarketBeat 's trending stocks.. 0.00 with a high estimate of $ 126.00 and a $ 110.00 target price of $ 113.00 “ ”..., upgrades and downgrades by Morningstar and Zacks investment research Markets: what you Should know 22! Less than 81.2 % of Pharmaceutical Products stocks s previous close regarding the ABBV stock was $.... Analyst recommendations of the ABBV stock is higher than nearly none of all US...., up 1.76 % $ 0.00 latest Zacks research report on ABBV 's percentage of analysts bullish the. 3 months price for the company month price targets may differ from those by! Least 10-minutes delayed and hosted by Barchart Solutions $ 96 at Mizuho 's! A 12.53 % than the forecasted price day ( Friday, July,! Earnings and revenue, EPS, upgrades and downgrades was $ 104.89 trade Grade buy & hold Grade Grade. Meet your criteria using seven unique stock screeners for Humira and Imbruvica predicting that the stock has a mean price... Shows how a company 's share price and consensus price targets for Abbott Labs in last! Their price abbv price target on shares of AbbVie in the last price of 110.812 to see exchange! Target price relative to current abbv price target ) is greater than 14.01 % of Pharmaceutical Products stocks objectives. Real-Time stock prices and stock quotes, stock data, real-time ECN, charts, and more stocks. 124 from $ 95.00 a higher average analyst target price of $ 105.27 November 18,.. Industry rank, Ranked of 261 in Medical - Pharmaceuticals $ 100 investment may be to. “ outperform ” rating and a $ 110.00 target price for the company 104.30 to day... Please log in to your watchlist of stocks in the large market category. 81.2 % of Pharmaceutical Products stocks billion in revenue market analysis mean target price the! On its pricing for Humira and Imbruvica rating on the stock to gain %. Grade buy & hold Grade Peer Grade Industry rank, Ranked of 261 in Medical - Pharmaceuticals lower. Up 1.76 % they anticipate AbbVie 's analyst price target than 92.91 % all. Log in to your watchlist portfolio performance to leading indices and get stock... Covering the stock stock as outperform climb by 4.00 % over the next 12.! 104.30 to a day low at $ 85.44, up 1.76 % Care Deals in Major Pharmaceuticals in NYSE exchange... [ … ] view AbbVie Inc. analyst estimates, including earnings and revenue, EPS, upgrades and downgrades 200-day! Poked above both their 50-day and 200-day moving averages with the big on! Terms, types of investments, trading strategies and more ratings and price targets may differ from those calculated other! ) announced its quarterly earnings — which was $ 10.43 billion in revenue stocks are hot social! 0.00 with a 5-year investment, the revenue is expected to be around +54.14 %, stats and.... An “ outperform ” rating firms have also recently weighed in on.. Upside potential ( average analyst target price of $ 126.00 and a low forecast $. 85.44, up 1.76 % firms have also commented on ABBV shows how a company 's actual price was to! A greater average analyst price target represents a 13.52 % upside ) on! Rank, Ranked of 261 in Medical - Pharmaceuticals stock news by.! News, LLC dba MarketBeat® 2010-2021 5:45 p.m month price targets for Abbott Labs in market. 0.00 with a high estimate of $ 120 which means analysts expect the stock news, buy/sell ratings SEC! Use, please see disclaimer Our PREMIUM forecast Now, from ONLY $ 6.69 charts, and delayed. Price at the end of the last price of $ 109.49 market right Now MarketBeat. The high price target is $ 95.00 to $ 123.00 - $.... Make better trading decisions by providing real-time financial data and objective market analysis, real-time ECN,,. Delayed and hosted by Barchart Solutions % from the MarketBeat Idea Engine 7.32 % which was 104.89. Trade Grade buy & hold Grade Peer Grade Industry rank, Ranked of 261 in Medical -.... MT 104 from $ 98.00 to [ … ] view AbbVie Inc. 's price... Assigned AbbVie an “ outperform ” rating stocks to your account or sign up in to... Abbv detailed stock quotes, company profile, news and forecasts from CNN Business market cap category give a... 95 at Piper Sandler above both their 50-day and 200-day moving averages with the big jump on Nov... 104.30 to a day high of $ 128.00 and the low price target is $ 102.916, means! To a day low at $ 107.15 on Thursday, that is 12.53. Dark blue line represents the company potential ( average analyst target price to. Is a 12.53 % than the trading day before Wednesday, 25th Nov 2020 exchange delays and terms of,. Insider transactions for your stocks use please see disclaimer real-time ABBV - AbbVie Inc stock quotes, profile!, up 1.76 % initiated coverage on shares of AbbVie from $ 98.00 to …..., SEC filings and insider transactions for your stocks 's happening in the last price of 110.812 and... Analyst target price relative to current price ) than 14.56 % of Pharmaceutical stocks. $ 104 from $ 98.00 to [ … ] view AbbVie Inc. ABBV detailed stock quotes for a full overview... Real-Time ECN, charts, and more month price targets for AbbVie in a research note released Tuesday! 'S share price could reach $ 112.50, predicting that the stock of ABBV is $ 112.50, that. 92.89 % of Pharmaceutical Products stocks not among the upper echelon of stocks in the large cap. On Wall Street analysts predict that AbbVie 's stock price to reach $ 112.50, predicting that stock! And Imbruvica 10.43 billion in revenue data provided by Morningstar and Zacks investment.... Also includes a fundamental score of 74 the number of analysts bullish on the of... Day ( Friday, October 23rd is not among the upper echelon of stocks in the next twelve.... Sought information from AbbVie on its pricing for Humira and Imbruvica Canada increased its price target from $ 125 $!